Revance Therapeutics reported $-64342000 in Net Income for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Net Income Change
Abbvie ABBV:US $ 4490M 446M
Aerie Pharmaceuticals AERI:US $ -35.89M 81.42M
ALKERMES ALKS:US $ -35.9M 36.78M
Bristol Myers Squibb BMY:US $ 1278M 1094M
Cara Therapeutics CARA:US $ -27749000 5.63M
Coherus Biosciences CHRS:US $ -96.08M 50.36M
Eli Lilly And LLY:US $ 1902.9M 176.8M
Endo International Ordinary Shares ENDP:US $ -71.97M 490.09M
Horizon Pharma HZNP:US $ 204.26M 31.08M
JAZZ PHA JAZZ:US $ 1.65M 37M
Johnson & Johnson JNJ:US $ 5149M 413M
Merk MRK:US $ 4310M 552M
Neurocrine Biosciences NBIX:US $ 13.9M 21.2M
Pacira Pharmaceuticals PCRX:US $ 6.83M 11.96M
Procter & Gamble PG:US $ 3355M 868M
Revance Therapeutics RVNC:US $ -64.34M 1.24M
Supernus Pharmaceuticals SUPN:US $ 25.62M 23.17M
Teva Pharmaceutical Industries TEVA:US $ -955M 797M